Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg administered twice a day orally versus a placebo as a modifying treatment of the disease in patients with the progressive forms of Multiple Sclerosis (MS).

The principal outcome is to determine the efficacy, of andrographolide in retarding the progression of brain atrophy in patients with progressive forms of MS.


Clinical Trial Description

1. Evaluate the clinical efficacy of andrographolide 140 mg administered orally twice a day versus a placebo in:

- Delay in the disability capacity progression through the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC) at 24 months compared to the baseline.

- Delay in cognitive impairment by means of Paced Auditory Serial Addition Test (PASAT), Symbol Digit Modalities Test (SDMT) and depression (Beck) at 24 months compared to the baseline.

- Quality of life Multiple Sclerosis Impact Scale (MSIS 29) and fatigue (Krupp) through parameters reported by the patients at at 24 months compared to the baseline.

- Tolerability of andrographolide measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) at 24 months.

- Delay in the decrease in brain volume measured by Magnetic Resonance (MR) at 24 months compared to the baseline.

- Number and volume of new lesions or larger size in T2 by MR at 24 months compared to the baseline.

- Number of new hipointense lesions in T1 or (gadolinium captive) by MR at 24 months compared to the baseline.

- Delay in the retineal thinning measured by Optical Coherence Tomography (OCT) and visual field at 24 months compared to the baseline.

- Safety of andrographolide at 24 months through the record of adverse effects in symptom dairy and programmed interviews.

2. Explore the pharmacokinetic of andrographolide 140 mg administered orally twice day in:

- bio availability and concentration of andrographolide in the patients with treatment.

- half-life, maximum concentration, clearance of andrographolide in equilibrium state.

3. Determine the immunomodulatory effects of andrographolide 140 mg administered twice a day orally on lymphocyte populations in patients through the:

- Determination of Th1, Th2, Th17 and Treg lymphocyte sub-populations.

- Determination of cytokines IFNgama, TNFalpha, IL2, IL17alpha and TGFbeta.

Population: adult patients, men and women with progressive forms of MS. The number of patients to be selected will be 68, to randomly assign 34 patients to each group. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Multiple Sclerosis
  • Multiple Sclerosis, Chronic Progressive
  • Multiple Sclerosis, Secondary Progressive
  • Primary Progressive Multiple Sclerosis
  • Sclerosis

NCT number NCT02273635
Study type Interventional
Source Innobioscience SpA
Contact Claudia A Carcamo, MD, PhD
Phone +56223546885
Email ccarcamo@med.puc.cl
Status Recruiting
Phase Phase 1/Phase 2
Start date September 2014
Completion date April 2017

See also
  Status Clinical Trial Phase
Completed NCT02549703 - Mitochondrial Dysfunction and Disease Progression
Withdrawn NCT05029609 - Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS Phase 1
Terminated NCT03283826 - Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis Phase 1/Phase 2
Active, not recruiting NCT05974839 - Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
Active, not recruiting NCT05974852 - Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS
Recruiting NCT04977622 - Gray Matter Demyelination in Primary Progressive MS at 7T
Recruiting NCT05893225 - Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration Phase 2
Completed NCT03094364 - Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis N/A
Completed NCT02253264 - A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Phase 1
Recruiting NCT03691077 - Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714 Phase 3
Completed NCT00950248 - Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS) Phase 1/Phase 2
Active, not recruiting NCT05232825 - A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis Phase 3
Recruiting NCT05229861 - The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS N/A
Completed NCT01077466 - Natalizumab Treatment of Progressive Multiple Sclerosis Phase 2
Completed NCT01854359 - Idebenone for Primary Progressive Multiple Sclerosis Phase 1/Phase 2
Completed NCT03493841 - Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis Phase 1
Active, not recruiting NCT03562975 - Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Completed NCT00731692 - FTY720 in Patients With Primary Progressive Multiple Sclerosis Phase 3
Recruiting NCT04943289 - Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis Phase 1
Completed NCT01776060 - Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study